POTI', Francesco
 Distribuzione geografica
Continente #
NA - Nord America 3.561
AS - Asia 3.004
EU - Europa 2.042
SA - Sud America 442
AF - Africa 186
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 2
Totale 9.244
Nazione #
US - Stati Uniti d'America 3.478
SG - Singapore 1.146
CN - Cina 789
IT - Italia 515
VN - Vietnam 396
BR - Brasile 345
IE - Irlanda 318
HK - Hong Kong 250
SE - Svezia 245
FI - Finlandia 210
DE - Germania 192
ZA - Sudafrica 143
BD - Bangladesh 142
UA - Ucraina 125
FR - Francia 98
NL - Olanda 94
TR - Turchia 82
RU - Federazione Russa 70
GB - Regno Unito 50
CA - Canada 49
AR - Argentina 47
AT - Austria 44
IN - India 32
ID - Indonesia 20
IQ - Iraq 19
JP - Giappone 19
KR - Corea 18
MX - Messico 17
BE - Belgio 16
CZ - Repubblica Ceca 13
PL - Polonia 13
CL - Cile 11
EC - Ecuador 10
PK - Pakistan 10
CI - Costa d'Avorio 9
SA - Arabia Saudita 9
JO - Giordania 8
MY - Malesia 8
PH - Filippine 8
UZ - Uzbekistan 8
CO - Colombia 7
ES - Italia 7
EU - Europa 7
TN - Tunisia 7
VE - Venezuela 7
PY - Paraguay 6
TW - Taiwan 6
AE - Emirati Arabi Uniti 5
EG - Egitto 5
IR - Iran 5
MA - Marocco 5
RO - Romania 5
AL - Albania 4
BG - Bulgaria 4
LT - Lituania 4
TH - Thailandia 4
UY - Uruguay 4
CR - Costa Rica 3
DZ - Algeria 3
ET - Etiopia 3
GR - Grecia 3
JM - Giamaica 3
KE - Kenya 3
KZ - Kazakistan 3
NP - Nepal 3
AU - Australia 2
AZ - Azerbaigian 2
BO - Bolivia 2
BY - Bielorussia 2
HN - Honduras 2
HR - Croazia 2
PE - Perù 2
PS - Palestinian Territory 2
TT - Trinidad e Tobago 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BS - Bahamas 1
BT - Bhutan 1
BZ - Belize 1
CG - Congo 1
CH - Svizzera 1
DO - Repubblica Dominicana 1
GF - Guiana Francese 1
GH - Ghana 1
GT - Guatemala 1
HU - Ungheria 1
KW - Kuwait 1
LB - Libano 1
LV - Lettonia 1
MD - Moldavia 1
MK - Macedonia 1
ML - Mali 1
MN - Mongolia 1
NA - Namibia 1
NG - Nigeria 1
PA - Panama 1
PR - Porto Rico 1
Totale 9.236
Città #
Singapore 584
Ashburn 386
San Jose 353
Chandler 349
Dublin 318
Santa Clara 285
Hong Kong 232
Dallas 205
Beijing 204
Ann Arbor 145
Jacksonville 142
Johannesburg 129
Ho Chi Minh City 122
Parma 112
Dearborn 108
New York 107
Boardman 103
Hanoi 95
Houston 87
Princeton 73
Izmir 68
Nanjing 65
Lauterbourg 62
Los Angeles 57
Chicago 55
Wilmington 52
Hefei 47
Shanghai 44
Vienna 36
Columbus 35
Helsinki 33
Moscow 32
San Mateo 31
Toronto 31
Munich 30
São Paulo 29
Buffalo 28
Bremen 27
Milan 27
Council Bluffs 26
Nanchang 24
Des Moines 23
Seattle 23
Haiphong 22
Bologna 20
Hebei 20
Jinan 20
Rho 20
Shenyang 20
The Dalles 18
Brussels 16
Frankfurt am Main 16
Tokyo 16
Jakarta 15
Jiaxing 15
Brooklyn 14
Changsha 14
Da Nang 14
Fremont 14
Guangzhou 14
Tianjin 14
Belo Horizonte 13
Orem 13
Rome 12
Seoul 12
Kunming 11
Modena 11
Brno 10
Fairfield 10
Rio de Janeiro 10
Turku 10
Abidjan 9
Denver 9
Naples 9
San Francisco 9
Warsaw 9
Washington 9
Zhengzhou 9
Biên Hòa 8
Manchester 8
Nuremberg 8
Stockholm 8
Amman 7
Chengdu 7
Grafing 7
Hangzhou 7
London 7
Montreal 7
Phoenix 7
Redondo Beach 7
Tashkent 7
Turin 7
Baghdad 6
Hillsboro 6
Hải Dương 6
Marseille 6
Riyadh 6
Rockville 6
Uberlândia 6
Amsterdam 5
Totale 5.650
Nome #
Treatments for COVID-19: emerging drugs against the coronavirus 255
PCSK9 ablation attenuates Aβ pathology, neuroinflammation and cognitive dysfunctions in 5XFAD mice 249
Identification of 4-amino-2-Pyridones as new potent PCSK9 inhibitors: From phenotypic hit discovery to in vivo tolerability 234
Abacavir, nevirapine, and ritonavir modulate intracellular calcium levels without affecting GHRH-mediated growth hormone secretion in somatotropic cells in vitro 216
Effects of the radiocontrast agent iodixanol on endothelial cell morphology and function. 196
Impact of S1P mimetics on mesenteric ischemia/reperfusion injury 186
A Short Term Administration of Cyclosporine A to Mice Inhibits the Reverse Cholesterol Transport from Macrophages 177
Alcohol pattern consumption differently affects the efficiency of macrophage reverse cholesterol transport in vivo 167
CYCLOSPORINE A IMPAIRS THE REVERSE CHOLESTEROL TRANSPORT FROM MACROPHAGES IN VIVO BY REDUCING STEROL FECAL EXCRETION 164
Polyphenol health effects on cardiovascular and neurodegenerative disorders: A review and meta-analysis 164
PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) GENETIC DELETION ATTENUATES AMYLOID-. PATHOLOGY, NEUROINFLAMMATION AND IMPROVES COGNITIVE FUNCTIONS IN AN ALZHEIMER'S DISEASE MOUSE MODEL 162
Macrophage, But Not Systemic, Apolipoprotein E Is Necessary for Macrophage Reverse Cholesterol Transport In Vivo 154
Drug-drug interactions in polypharmacy patients: The impact of renal impairment 151
EFFETTI DEI MEZZI DI CONTRASTO E DELLA N-ACETILCISTEINA SU MORFOLOGIA E FUNZIONE DELLE CELLULE ENDOTELIALI UMANE 150
Cyclosporine A modulates the macrophage reverse cholesterol transport in vivo 147
Critical and emerging topics in dietary carbohydrates and health 144
Cyclosporine A Impairs the Macrophage Reverse Cholesterol Transport in Mice by Reducing Sterol Fecal Excretion 143
LA CICLOSPORINA A INIBISCE IL TRASPORTO INVERSO DEL COLESTEROLO NEI TOPI 142
CYCLOSPORINE A IMPAIRS THE REVERSE CHOLESTEROL TRANSPORT FROM MACROPHAGES IN VIVO BY REDUCING STEROL FECAL EXCRETION 142
LA CICLOSPORINA A RIDUCE IL TRASPORTO INVERSO DEL COLESTEROLO NEI TOPI ATTRAVERSO L’INIBIZIONE DELL’ESCREZIONE FECALE 142
Effetto della Ciclosporina A sul trasporto inverso del colesterolo in vivo 141
HDL and reverse cholesterol transport in humans and animals: Lessons from pre-clinical models and clinical studies 140
A SHORT TERM ADMINISTRATION OF CYCLOSPORINE A IMPAIRS THE REVERSE CHOLESTEROL TRANSPORT FROM MACROPHAGES IN VIVO 138
EFFECTS OF RADIOLOGY CONTRAST MEDIA ON CULTURED HUMAN ENDOTHELIAL CELL MORPHOLOGY AND FUNCTION AND PROTECTIVE ACTION OF N-ACETYLCYSTEIN AND ROSUVASTATIN 135
Identification of sclerostin as a putative new myokine involved in the muscle-to-bone crosstalk 135
'Spare' Luteinizing Hormone Receptors: Facts and Fiction 133
Effetto degli agonisti LXR sul trasporto inverso del colesterolo in vivo 133
Clusterin enhances AKT2-mediated motility of normal and cancer prostate cells through a PTEN and PHLPP1 circuit 131
RUOLO DELLA SFINGOSINA 1-FOSFATO E DEL SUO RECETTORE S1P3 NEL TRASPORTO INVERSO DEL COLESTEROLO 126
TRASPORTO INVERSO DEL COLESTEROLO: FATTORI DETERMINANTI L’EFFICIENZA DEL PROCESSO 120
The LXR agonist T0901317 promotes the reverse cholesterol transport frommacrophages by increasing plasma efflux potential 117
Macrophage, but not systemic, apolipoprotein E is necessary for macrophage reverse cholesterol transport in vivo 116
Aortic Gene Expression Profiles Show How ApoA-I Levels Modulate Inflammation, Lysosomal Activity, and Sphingolipid Metabolism in Murine Atherosclerosis 116
Dual effect of statins on ABCA1-mediated lipid efflux from macrophages and hepatic cells 113
Impact of dietary lipids on the reverse cholesterol transport: What we learned from animal studies 113
IN VIVO TREATMENT WITH CYCLOSPORINE A INCREASES EFFLUX POTENTIAL OF MOUSE PLASMA VIA ATP-BINDING CASSETTE TRANSPORTER ABCA1 112
Biglycan and atherosclerosis: Lessons from high cardiovascular risk conditions 112
ROLE OF APOLIPOPROTEIN E IN THE REVERSE CHOLESTEROL TRANSPORT IN VIVO 110
Cholesteryl ester transfer protein expression partially attenuates the adverse effects of SR-BI receptor deficiency on cholesterol metabolism and atherosclerosis 110
Atheroprotective role of high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P) 109
Impact of apolipoprotein E (apoE) deficiency on reverse cholesterol transport in vivo 107
Apolipoprotein M and Sphingosine-1-Phosphate Receptor 1 Promote the Transendothelial Transport of High-Density Lipoprotein 107
Sphingosine-1 phosphate induces cAMP/PKA-independent phosphorylation of the cAMP response element-binding protein (CREB) in granulosa cells 104
Gnrh antagonists produce differential modulation of the signaling pathways mediated by gnrh receptors 102
Effect of LXR agonists on reverse cholesterol transport in vivo 100
Pitavastatin effect on ATP binding cassette A1-mediated lipid efflux from macrophages: evidence for liver X receptor (LXR)-dependent and LXR-independent mechanisms of activation by cAMP 99
LH increases the response to FSH in granulosa-lutein cells from sub/poor-responder patients in vitro 97
Elevating Endogenous Sphingosine-1-Phosphate (S1P) Levels Improves Endothelial Function and Ameliorates Atherosclerosis in Low Density Lipoprotein Receptor-Deficient (LDL-R-/-) Mice 97
Sphingosine-1-phosphate receptor 3 regulates the transendothelial transport of high-density lipoproteins and low-density lipoproteins in opposite ways 95
Glycosylation pattern and in vitro bioactivity of reference follitropin alfa and biosimilars 95
Targeted invalidation of SR-B1 in macrophages reduces macrophage apoptosis and accelerates atherosclerosis 93
The liver-X-receptor agonist T0901317 stimulates in vivo reverse cholesterol transport in mice 92
Pharmacogenetics of GPCR variants: FSH receptor and infertility treatment 91
Meccanismo di attivazione dell’ATP-binding cassette A1 da parte del cAMP 89
Enhanced expression of the sphingosine-1-phosphate-receptor-3 causes acute myelogenous leukemia in mice 89
COVID-19 … What are drugs and strategies now? 87
Effect of the LXR agonist T0901317 on reverse cholesterol transport in vivo 86
La rosuvastatina promuove il trasporto inverso del colesterolo nei topi 86
EFFECTS OF RADIOLOGY CONTRAST MEDIA ON CULTURED HUMAN ENDOTHELIAL CELL MORPHOLOGY AND FUNCTION AND PROTECTIVE ACTION OF N-ACETYLCYSTEIN AND ROSUVASTATIN 86
Editorial: Pharmacology of endocrine related GPCRs 85
The in vivo stimulation of LXR promotes the reverse cholesterol transport in vivo by increasing the efflux potential of sera 85
Il cAMP attiva l’ATP-Binding Cassette A1 (ABCA1) attraverso un duplice meccanismo 83
SKI-II - a sphingosine kinase 1 inhibitor - exacerbates atherosclerosisin low-density lipoprotein receptor-deficient (LDL-R-/-) mice on high cholesterol diet 82
Inferring biallelism of two FSH receptor mutations associated with spontaneous ovarian hyperstimulation syndrome by evaluating FSH, LH and HCG cross-activity 82
The LXR agonist T0901317 increases the efflux potential of sera and promotes the reverse cholesterol transport in mice 81
In vivo stimulation of LXR increases the efflux potential of sera and promotes the reverse cholesterol transport 79
Human LH and hCG stimulate differently the early signalling pathways but result in equal testosterone synthesis in mouse Leydig cells in vitro 77
WISP-2 expression induced by Teriparatide treatment affects in vitro osteoblast differentiation and improves in vivo osteogenesis 76
High density lipoprotein (HDL)-associated sphingosine 1-phosphate (S1P) inhibits macrophage apoptosis by stimulating STAT3 activity and survivin expression 76
Seizures of illicit substances for personal use in two Italian provinces: Analysis of trends by type and purity from 2008 to 2017 76
Sphingosine 1-phosphate receptor 1 signaling in macrophages reduces atherosclerosis in LDL receptor–deficient mice 74
Sphingolipids and atherosclerosis: focus on Sphingosine 1-Phosphate (S1P) 74
Effect of sphingosine 1-phosphate (S1P) receptor agonists FTY720 and CYM5442 on atherosclerosis development in LDL receptor deficient (LDL-R-/-) mice 72
KRP-203, sphingosine 1-phosphate receptor type 1 agonist, ameliorates atherosclerosis in LDL-R-/-mice 71
Sphingosine 1-Phosphate (S1P): a bridge between HDL, inflammation and atherosclerosis? 70
Sphingosine kinase inhibition exerts both pro- and anti-atherogenic effects in low-density lipoprotein receptor-deficient (LDL-R -/-) mice 67
Membrane Estrogen Receptor (GPER) and Follicle-Stimulating Hormone Receptor (FSHR) Heteromeric Complexes Promote Human Ovarian Follicle Survival 63
Osteocytes specific GSK3 inhibition affects in vitro osteogenic differentiation 59
The “hitchhiker’s guide to the galaxy” of endothelial dysfunction markers in human fertility 58
Molecular basis of androgen action on human sexual desire 56
Treatments for COVID-19: Emerging drugs against the coronavirus-reply 54
Totale 9.347
Categoria #
all - tutte 33.814
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.814


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202129 0 0 0 0 0 0 0 0 0 0 0 29
2021/2022399 21 15 16 9 25 18 65 54 20 27 6 123
2022/20231.260 140 100 79 114 131 147 13 89 380 14 41 12
2023/2024557 23 42 13 21 26 140 31 54 19 34 45 109
2024/20251.732 46 88 115 126 185 210 49 63 231 152 134 333
2025/20263.781 356 396 443 273 578 147 397 162 407 248 264 110
Totale 9.347